Last reviewed · How we verify
Single Dose Liposomal Bupivicaine
Liposomal bupivacaine is a local anesthetic encapsulated in liposomes that provides prolonged nerve blockade by slowly releasing bupivacaine at the injection site.
Liposomal bupivacaine is a local anesthetic encapsulated in liposomes that provides prolonged nerve blockade by slowly releasing bupivacaine at the injection site. Used for Infiltration anesthesia and nerve block for surgical anesthesia and postoperative analgesia.
At a glance
| Generic name | Single Dose Liposomal Bupivicaine |
|---|---|
| Also known as | TAP block with liposomal bupivacaine |
| Sponsor | University of California, Davis |
| Drug class | Local anesthetic (liposomal formulation) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Pain Management |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine blocks sodium channels in nerve cell membranes to prevent action potential propagation and pain signal transmission. By encapsulating bupivacaine in liposomal vesicles, the formulation extends drug release over 72 hours or longer, providing sustained local anesthesia and analgesia compared to conventional bupivacaine solutions. This allows for single-dose administration with extended pain relief in surgical and regional anesthesia settings.
Approved indications
- Infiltration anesthesia and nerve block for surgical anesthesia and postoperative analgesia
Common side effects
- Injection site reactions (pain, erythema, edema)
- Headache
- Nausea
- Dizziness
- Systemic toxicity (rare at recommended doses)
Key clinical trials
- TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (PHASE4)
- RCT Comparing ESPB Solutions in Breast Surgery (PHASE2)
- 0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka (PHASE3)
- Study of Exparel Versus Epidural for Pain Control After Thoracotomy (PHASE4)
- Exparel for Pain Control During Care of Rib Fractures (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single Dose Liposomal Bupivicaine CI brief — competitive landscape report
- Single Dose Liposomal Bupivicaine updates RSS · CI watch RSS
- University of California, Davis portfolio CI